Biomarker Discovery and Data Visualization Tool for Ovarian Cancer Screening
نویسندگان
چکیده
منابع مشابه
Metabolite differentiation and discovery lab (MeDDL): a new tool for biomarker discovery and mass spectral visualization.
The goal of this work was to design and implement a prototype software tool for the visualization and analysis of small molecule metabolite GC-MS and LC-MS data for biomarker discovery. The key features of the Metabolite Differentiation and Discovery Lab (MeDDL) software platform include support for the manipulation of large data sets, tools to provide a multifaceted view of the individual expe...
متن کاملExploring the Immunoproteome for Ovarian Cancer Biomarker Discovery
Most scientific efforts towards early detection of ovarian cancer are commonly focused on the discovery of tumour-associated antigens (TAA). Autologous antibodies against TAA, however, may serve as more sensitive diagnostic markers. They circulate in the blood before TAA and are usually more abundant than the TAAs themselves as a result of amplification through the humoral immune response. Accu...
متن کاملOvarian Cancer Biomarker Discovery Based on Genomic Approaches
Ovarian cancer presents at an advanced stage in more than 75% of patients. Early detection has great promise to improve clinical outcomes. Although the advancing proteomic technologies led to the discovery of numerous ovarian cancer biomarkers, no screening method has been recommended for early detection of ovarian cancer. Complexity and heterogeneity of ovarian carcinogenesis is a major obstac...
متن کاملOvarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
Establishing a cancer screening biomarker's intended performance requires "phase III" specimens obtained in asymptomatic individuals before clinical diagnosis rather than "phase II" specimens obtained from symptomatic individuals at diagnosis. We used specimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate ovarian cancer biomarkers previously assesse...
متن کاملColorectal, and Ovarian Cancer Screening Trial Specimens Ovarian Cancer Biomarker Performance in Prostate, Lung,
Establishing a cancer screening biomarker’s intended performance requires "phase III" specimens obtained in asymptomatic individuals before clinical diagnosis rather than "phase II" specimens obtained from symptomatic individuals at diagnosis. We used specimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate ovarian cancer biomarkers previously assesse...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Bio-Science and Bio-Technology
سال: 2014
ISSN: 2233-7849,2233-7849
DOI: 10.14257/ijbsbt.2014.6.2.17